Exact Sciences (EXAS) Tops Q4 EPS by 7c; Offers Guidance

Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of ($0.72), $0.07 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $553 million versus the consensus estimate of $524.51 million.

GUIDANCE:

Exact Sciences sees FY2023 revenue of $2265-2315 million, versus the consensus of $2289 million.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.

You May Also Be Interested In

• Phibro Animal Health (PAHC) Tops Q4 EPS by 13c; Offers Guidance
• CrowdStrike Holdings Inc. (CRWD) Tops Q2 EPS by 2c, Beats on Revenue; Offers FY Guidance
• Veeva Systems (VEEV) Tops Q2 EPS by 13c; Offers Guidance